Pulmonology

Vasculitis

Questions discussed in this category

Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?

Would you suggest switching to a viral vector vaccine, such as J&J?

2 Answers available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?

Would you change rituximab maintenance dose or schedule?

1 Answer available

How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?

1 Answer available

How do you treat an AAV patient with recurrent bronchial stenosis that has not responded to rituximab induction therapy and dilatations?

1 Answer available

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

1 Answer available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

2 Answers available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

2 Answers available

What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?

1 Answer available

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

2 Answers available

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

1 Answer available

When do you stop immunosuppressants in patients with GPA?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

The New England journal of medicine, 2017-05-18

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Kidney international reports, 2018-03

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Rheumatology (Oxford),

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Ann Intern Med,

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Ann Rheum Dis, 2011 Nov 29

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

RMD Open, 2021 Sep

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Pulmonology

Vasculitis

Questions discussed in this category

Papers discussed in this category

Related Topics in Pulmonology